Fast Five Quiz: Heart Failure Comorbidities

Ioana Dumitru, MD; Jeffrey J. Hsu, MD


December 09, 2022

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as an important therapy for patients with type 2 diabetes and cardiovascular disease. Randomized clinical trials have demonstrated that SGLT2 inhibitors reduce the risk for major adverse cardiovascular events and HF-related hospitalization in patients with HF, regardless of ejection fraction or diabetes status.

Observational studies have consistently demonstrated an increased risk for HF in patients with diabetes compared with patients without diabetes. According to Ohkuma and colleagues, the prevalence of HF is greater among patients with type 1 diabetes compared with patients with type 2 diabetes, and the relative risk is even higher among women.

Insulin resistance may be present in > 60% of individuals with HF. Data from the CHARM study found that the prevalence of diagnosed diabetes is higher among patients with HFpEF (40%) compared with those with HFrEF (35%). However, the prevalence of dysglycemia was similar and associated with a higher risk for adverse clinical outcomes in patients with both HF phenotypes.

Available data suggest that intensive glycemic control in patients with diabetes does not lessen the risk for HF.

Learn more about HF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.